vs
Ametek（AME）与NEOGENOMICS INC（NEO）财务数据对比。点击上方公司名可切换其他公司
Ametek的季度营收约是NEOGENOMICS INC的10.5倍（$2.0B vs $190.2M）。Ametek同比增速更快（13.4% vs 10.6%）。Ametek自由现金流更多（$527.3M vs $-6.5M）。过去两年NEOGENOMICS INC的营收复合增速更高（10.3% vs 7.3%）
AMETEK Inc.是美国跨国综合企业，为全球知名的电子仪器及机电设备设计商与制造商，总部位于美国，在全球范围内设有超过150个运营站点，业务覆盖多个国家和地区，为各行业客户提供高性能的相关产品及配套解决方案。
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
AME vs NEO — 直观对比
营收规模更大
AME
是对方的10.5倍
$190.2M
营收增速更快
AME
高出2.9%
10.6%
自由现金流更多
AME
多$533.8M
$-6.5M
两年增速更快
NEO
近两年复合增速
7.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $190.2M |
| 净利润 | $398.6M | — |
| 毛利率 | 36.0% | 43.8% |
| 营业利润率 | 25.3% | -7.1% |
| 净利率 | 19.9% | — |
| 营收同比 | 13.4% | 10.6% |
| 净利润同比 | 2.9% | — |
| 每股收益（稀释后） | $1.73 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMENEO
| Q4 25 | $2.0B | $190.2M | ||
| Q3 25 | $1.9B | $187.8M | ||
| Q2 25 | $1.8B | $181.3M | ||
| Q1 25 | $1.7B | $168.0M | ||
| Q4 24 | $1.8B | $172.0M | ||
| Q3 24 | $1.7B | $167.8M | ||
| Q2 24 | $1.7B | $164.5M | ||
| Q1 24 | $1.7B | $156.2M |
净利润AMENEO
| Q4 25 | $398.6M | — | ||
| Q3 25 | $371.4M | $-27.1M | ||
| Q2 25 | $358.4M | $-45.1M | ||
| Q1 25 | $351.8M | $-25.9M | ||
| Q4 24 | $387.3M | — | ||
| Q3 24 | $340.2M | $-17.7M | ||
| Q2 24 | $337.7M | $-18.6M | ||
| Q1 24 | $310.9M | $-27.1M |
毛利率AMENEO
| Q4 25 | 36.0% | 43.8% | ||
| Q3 25 | 36.3% | 42.8% | ||
| Q2 25 | 35.8% | 42.6% | ||
| Q1 25 | 36.1% | 43.6% | ||
| Q4 24 | 36.6% | 44.9% | ||
| Q3 24 | 36.0% | 44.6% | ||
| Q2 24 | 36.0% | 44.1% | ||
| Q1 24 | 34.1% | 41.9% |
营业利润率AMENEO
| Q4 25 | 25.3% | -7.1% | ||
| Q3 25 | 25.8% | -14.4% | ||
| Q2 25 | 26.0% | -26.3% | ||
| Q1 25 | 26.3% | -16.6% | ||
| Q4 24 | 26.6% | -10.7% | ||
| Q3 24 | 26.1% | -12.6% | ||
| Q2 24 | 25.8% | -13.3% | ||
| Q1 24 | 24.0% | -19.6% |
净利率AMENEO
| Q4 25 | 19.9% | — | ||
| Q3 25 | 19.6% | -14.4% | ||
| Q2 25 | 20.2% | -24.9% | ||
| Q1 25 | 20.3% | -15.4% | ||
| Q4 24 | 22.0% | — | ||
| Q3 24 | 19.9% | -10.5% | ||
| Q2 24 | 19.5% | -11.3% | ||
| Q1 24 | 17.9% | -17.3% |
每股收益（稀释后）AMENEO
| Q4 25 | $1.73 | — | ||
| Q3 25 | $1.60 | — | ||
| Q2 25 | $1.55 | — | ||
| Q1 25 | $1.52 | — | ||
| Q4 24 | $1.67 | — | ||
| Q3 24 | $1.47 | — | ||
| Q2 24 | $1.45 | — | ||
| Q1 24 | $1.34 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $458.0M | $159.6M |
| 总债务越低越好 | $2.3B | $341.9M |
| 股东权益账面价值 | $10.6B | $836.6M |
| 总资产 | $16.1B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.21× | 0.41× |
8季度趋势，按日历期对齐
现金及短期投资AMENEO
| Q4 25 | $458.0M | $159.6M | ||
| Q3 25 | $439.2M | $164.1M | ||
| Q2 25 | $619.7M | $154.7M | ||
| Q1 25 | $399.0M | $346.2M | ||
| Q4 24 | $374.0M | $367.0M | ||
| Q3 24 | $396.3M | $362.0M | ||
| Q2 24 | $396.6M | $355.1M | ||
| Q1 24 | $373.8M | $331.9M |
总债务AMENEO
| Q4 25 | $2.3B | $341.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1B | $541.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AMENEO
| Q4 25 | $10.6B | $836.6M | ||
| Q3 25 | $10.5B | $838.3M | ||
| Q2 25 | $10.4B | $854.0M | ||
| Q1 25 | $10.0B | $888.3M | ||
| Q4 24 | $9.7B | $902.3M | ||
| Q3 24 | $9.6B | $908.2M | ||
| Q2 24 | $9.3B | $915.9M | ||
| Q1 24 | $9.0B | $923.4M |
总资产AMENEO
| Q4 25 | $16.1B | $1.4B | ||
| Q3 25 | $16.2B | $1.4B | ||
| Q2 25 | $15.3B | $1.4B | ||
| Q1 25 | $14.9B | $1.6B | ||
| Q4 24 | $14.6B | $1.6B | ||
| Q3 24 | $14.8B | $1.6B | ||
| Q2 24 | $14.8B | $1.6B | ||
| Q1 24 | $14.9B | $1.6B |
负债/权益比AMENEO
| Q4 25 | 0.21× | 0.41× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | 0.60× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.3M | $1.3M |
| 自由现金流经营现金流 - 资本支出 | $527.3M | $-6.5M |
| 自由现金流率自由现金流/营收 | 26.4% | -3.4% |
| 资本支出强度资本支出/营收 | 2.9% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.47× | — |
| 过去12个月自由现金流最近4个季度 | $1.7B | $-21.8M |
8季度趋势，按日历期对齐
经营现金流AMENEO
| Q4 25 | $584.3M | $1.3M | ||
| Q3 25 | $440.9M | $8.9M | ||
| Q2 25 | $359.1M | $20.3M | ||
| Q1 25 | $417.5M | $-25.3M | ||
| Q4 24 | $550.0M | $9.8M | ||
| Q3 24 | $487.2M | $9.2M | ||
| Q2 24 | $381.4M | $13.9M | ||
| Q1 24 | $410.2M | $-25.9M |
自由现金流AMENEO
| Q4 25 | $527.3M | $-6.5M | ||
| Q3 25 | $420.0M | $570.0K | ||
| Q2 25 | $329.8M | $14.0M | ||
| Q1 25 | $394.5M | $-29.8M | ||
| Q4 24 | $498.3M | $-1.8M | ||
| Q3 24 | $460.9M | $-1.6M | ||
| Q2 24 | $360.0M | $814.0K | ||
| Q1 24 | $382.6M | $-31.5M |
自由现金流率AMENEO
| Q4 25 | 26.4% | -3.4% | ||
| Q3 25 | 22.2% | 0.3% | ||
| Q2 25 | 18.5% | 7.7% | ||
| Q1 25 | 22.8% | -17.8% | ||
| Q4 24 | 28.3% | -1.0% | ||
| Q3 24 | 27.0% | -0.9% | ||
| Q2 24 | 20.8% | 0.5% | ||
| Q1 24 | 22.0% | -20.2% |
资本支出强度AMENEO
| Q4 25 | 2.9% | 4.1% | ||
| Q3 25 | 1.1% | 4.4% | ||
| Q2 25 | 1.6% | 3.5% | ||
| Q1 25 | 1.3% | 2.7% | ||
| Q4 24 | 2.9% | 6.7% | ||
| Q3 24 | 1.5% | 6.4% | ||
| Q2 24 | 1.2% | 8.0% | ||
| Q1 24 | 1.6% | 3.6% |
现金转化率AMENEO
| Q4 25 | 1.47× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 1.42× | — | ||
| Q3 24 | 1.43× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AME
| Transferred At Point In Time | $1.1B | 54% |
| Electronic Instruments Group | $620.1M | 31% |
| Transferred Over Time | $294.6M | 15% |
NEO
| Client Direct Billing | $133.4M | 70% |
| Commercial Insurance | $31.4M | 17% |
| Medicare And Other Governmental | $25.4M | 13% |
